Top

Journal of Experimental & Clinical Cancer Research

Published in:

Open Access 01-12-2019 | Biomarkers | Review

Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology

Authors: Neel I. Nissen, Morten Karsdal, Nicholas Willumsen

Published in: Journal of Experimental & Clinical Cancer Research | Issue 1/2019

Abstract

The extracellular matrix (ECM) plays an important role in cancer progression. It can be divided into the basement membrane (BM) that supports epithelial/endothelial cell behavior and the interstitial matrix (IM) that supports the underlying stromal compartment. The major components of the ECM are the collagens. While breaching of the BM and turnover of e.g. type IV collagen, is a well described part of tumorigenesis, less is known regarding the impact on tumorigenesis from the collagens residing in the stroma. Here we give an introduction and overview to the link between tumorigenesis and stromal collagens, with focus on the fibrillar collagens type I, II, III, V, XI, XXIV and XXVII as well as type VI collagen. Moreover, we discuss the impact of the cells responsible for this altered stromal collagen remodeling, the cancer associated fibroblasts (CAFs), and how these cells are key players in orchestrating the tumor microenvironment composition and tissue microarchitecture, hence also driving tumorigenesis and affecting response to treatment. Lastly, we discuss how specific collagen-derived biomarkers reflecting the turnover of stromal collagens and CAF activity may be used as tools to non-invasively interrogate stromal reactivity in the tumor microenvironment and predict response to treatment.

Theocharis AD, Skandalis SS, Gialeli C, Karamanos NK. Extracellular matrix structure. Adv Drug Deliv Rev. 2016;97:4–27. Available from:. https://doi.org/10.1016/j.addr.2015.11.001.PubMed

Frantz C, Stewart KM, Weaver VM. The extracellular matrix at a glance. J Cell Sci. 2010;123(24):4195–200. Available from:. https://doi.org/10.1242/jcs.023820.PubMedPubMedCentral

Ricard-blum S. The collagen family. Cold Spring Harb Perspect Biol. 2011;3(1):1–19.

Ivarsson M, McWhirter a, Borg TK, Rubin K. Type I collagen synthesis in cultured human fibroblasts: regulation by cell spreading, platelet-derived growth factor and interactions with collagen fibers. Matrix Biol. 1998;

Gay S, Martin GR, Muller PK, Timpl R, Kuhn K. Simultaneous synthesis of types I and III collagen by fibroblasts in culture. Proc Natl Acad Sci U S A. 1976;73(11):4037–40 Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=431318&tool=pmcentrez&rendertype=abstract.PubMedPubMedCentral

Sampath Narayanan A, Page RC. Synthesis of type V collagen by fibroblasts derived from Normal, inflamed and hyperplastic human connective tissues. Top Catal 1985;5(4):297–304. Available from: https://doi.org/10.1016/S0174-173X(85)80019-4

Zou Y, Zhang RZ, Sabatelli P, Chu ML, Bönnemann CG. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol. 2008.

Oxford JT, Doege KJ, Horton WE, Morris NP. Characterization of type II and type XI collagen synthesis by an immortalized rat chondrocyte cell line (IRC) having a low level of type II collagen mRNA expression. Exp Cell Res. 1994.

Bonnans C, Chou J, Werb Z. Remodelling the extracellular matrix in development and disease. Nat rev mol cell biol. 2014;15(12):786–801.PubMedPubMedCentral

10.

Mason SD, Joyce J. a. Proteolytic networks in Cancer. Trends Cell Biol. 2011;21(4):1–18.

11.

Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer. 2003;3(6):422–33.PubMed

12.

Tanjore H, Kalluri R. The role of type IV collagen and basement membranes in cancer progression and metastasis. Am J Pathol. 2006;168(3):715–7.PubMedPubMedCentral

13.

Xu J, Rodriguez D, Petitclerc E, Kim JJ, Hangai M, Moon Yuen S, et al. Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo. J Cell Biol. 2001;154(5):1069–79.PubMedPubMedCentral

14.

Xu J, Rodriguez D, Kim JJ, Brooks PC. Generation of monoclonal antibodies to cryptic collagen sites by using subtractive immunization. Hybridoma. 2000;19(5):375–85.PubMed

15.

O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277–85.PubMed

16.

Kalluri R. The biology and function of fibroblasts in cancer. Nat Rev Cancer. 2016;16(9):582–98. Available from:. https://doi.org/10.1038/nrc.2016.73.PubMed

17.

Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat Rev Cancer. 2006;6(5):392–401.PubMed

18.

Sasser K, Hall B. Encyclopedia of Cancer, Desmoplasia [internet]; 2011. Available from:. https://doi.org/10.1007/978-3-662-46875-3.

19.

Pankova D, Chen Y, Terajima M, Schliekelman MJ, Baird BN, Fahrenholtz M, et al. Cancer-associated fibroblasts induce a collagen cross-link switch in tumor stroma. Mol Cancer Res. 2016;14(3):287–95. Available from:. https://doi.org/10.1158/1541-7786.MCR-15-0307.PubMed

20.

Pickup MW, Mouw JK, Weaver VM. The extracellular matrix modulates the hallmarks of cancer. EMBO Rep. 2014 Dec;15(12):1243–53.PubMedPubMedCentral

21.

Bager CL, Willumsen N, Leeming DJ, Smith V, Karsdal MA, Dornan D, et al. Collagen degradation products measured in serum can separate ovarian and breast cancer patients from healthy controls: a preliminary study. Cancer Biomarkers. 2015;15(6):783–8.PubMed

22.

Willumsen N, Bager CL, Leeming DJ, Smith V, Karsdal M a, Dornan D, et al. Extracellular matrix specific protein fingerprints measured in serum can seperate pancreatic cancer patients from healthy controls. BMC Cancer [Internet]. 2013;13:554. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=4222497&tool=pmcentrez&rendertype=abstract%5Cnhttp://www.ncbi.nlm.nih.gov/pubmed/24261855

23.

Willumsen N, Bager CL, Leeming DJ, Smith V, Christiansen C, Karsdal MA, et al. Serum biomarkers reflecting specific tumor tissue remodeling processes are valuable diagnostic tools for lung cancer. Cancer Med. 2014;3(5):1136–45.PubMedPubMedCentral

24.

Kehlet SN, Sanz-Pamplona R, Brix S, Leeming DJ, Karsdal MA, Moreno V. Excessive collagen turnover products are released during colorectal cancer progression and elevated in serum from metastatic colorectal cancer patients. Sci Rep [Internet] 2016;6(July):1–7. Available from: https://doi.org/10.1038/srep30599

25.

Leeming DJ, Koizumi M, Qvist P, Barkholt V, Zhang C, Henriksen K, et al. Serum N-Terminal Propeptide of Collagen Type I is Associated with the Number of Bone Metastases in Breast and Prostate Cancer and Correlates to Other Bone Related Markers. Biomark Cancer [Internet]. 2011;3:15–23. Available from: https://www.ncbi.nlm.nih.gov/pubmed/24179387

26.

Cirri P, Chiarugi P. Cancer associated fibroblasts: the dark side of the coin. Am J Cancer Res [Internet] 2011;1(4):482–497. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3186047&tool=pmcentrez&rendertype=abstract

27.

Öhlund D, Elyada E, Tuveson D. Fibroblast heterogeneity in the cancer wound. J Exp Med [Internet] 2014;211(8):1503–1523. Available from: https://doi.org/10.1084/jem.20140692

28.

Meng X, Nikolic-Patersen D, Lan H. TGF-β the master regulator of fibrosis.Pdf. Nat Rev Nephrol. 2016;12(6):325–38.PubMed

29.

Mertens JC, Fingas CD, Christensen JD, Smoot RL, Bronk SF, Werneburg NW, et al. Therapeutic effects of deleting cancer-associated fibroblasts in cholangiocarcinoma. Cancer Res. 2013.

30.

Cadamura M, Indraccolo S, Dall'olmo L, Sambado L, Moserle L, Franceschet I, Colledan M, Massani M, Stecca T, Bassi N, Morton S, Spirli C, Fiorotto R, Fabris L, Strazzabosco M. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology 2013;58(3):1042–1053, PMID: 23505219. doi: https://doi.org/10.1002/hep.26384, Available from: https://www.ncbi.nlm.nih.gov/pubmed/23505219

31.

Radisky DC, Kenny PA, Bissel MJ. Fibrosis and Cancer: do Myofibroblasts come also from epithelial cells via EMT. NIH Public Access. 2007;101(4):830–9.

32.

Zeisberg EM, Potenta S, Xie L, Zeisberg M, Kalluri R. Discovery of endothelial to mesenchymal transition as a source for carcinoma-associated fibroblasts. Cancer Res. 2007;67(21):10123–8.PubMed

33.

Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: orchestrating the composition of malignancy. Genes Dev. 2016;30(9):1002–19.PubMedPubMedCentral

34.

Kauppila S, Stenback F, Risteli J, Jukkola A, Risteli L. Aberrant type I and type III collagen gene expression in human breast cancer in vivo. J Pathol. 1998;268(July):262–8.

35.

Hanley CJ, Noble F, Ward M, Bullock M, Drifka C, Mellone M, et al. A subset of myofibroblastic cancer-associated fibroblasts regulate collagen fiber elongation, which is prognostic in multiple cancers. Oncotarget [Internet] 2016;7(5):6159–6174. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26716418

36.

Öhlund D, Handly-Santana A, Biffi G, Elyada E, Almeida AS, Ponz-Sarvise M, et al. Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer. J Exp Med. 2017.

37.

Madar S, Goldstein I, Rotter V. “Cancer associated fibroblasts” - more than meets the eye. Trends in Molecular Medicine. 2013.

38.

Wagner EF. Cancer: fibroblasts for all seasons. Nature. 2016.

39.

Glentis A, Oertle P, Mariani P, Chikina A, El Marjou F, Attieh Y, et al. Cancer-associated fibroblasts induce metalloprotease-independent cancer cell invasion of the basement membrane. Nat Commun [Internet]. 2017;8(1):1–13. Available from: https://doi.org/10.1038/s41467-017-00985-8

40.

Alkasalias T, Moyano-Galceran L, Arsenian-Henriksson M, Lehti K. Fibroblasts in the tumor microenvironment: shield or spear? International journal of molecular sciences; 2018.

41.

Shekhar MP, Werdell J, Santner SJ, Pauley RJ, Tait L. Breast stroma plays a dominant regulatory role in breast epithelial growth and differentiation: implications for tumor development and progression. Cancer res [internet]. 2001;61(4):1320–1326. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11245428.

42.

Kuperwasser C, Chavarria T, Wu M, Magrane G, Gray JW, Carey L, et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci U S A [Internet] 2004;101(14):4966–4971. Available from: https://www.ncbi.nlm.nih.gov/pubmed/15051869

43.

Olumi AF, Grossfeld GD, Hayward SW, Carroll PR, Tlsty TD, Cunha GR. Carcinoma-associated Fibroblasts Direct Tumor Progression of Initiated HumanProstatic Epithelium.pdf. Ep Prostatic. 1999;5002–5011.

44.

Orimo A, Gupta PB, Sgroi DC, Arenzana-Seisdedos F, Delaunay T, Naeem R, et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 2005;121(3):335–48.PubMed

45.

Wang L, Cao L, Wang H, Liu B, Zhang Q, Meng Z, et al. Cancer-associated fibroblasts enhance metastatic potential of lung cancer cells through IL-6/STAT3 signaling pathway. Oncotarget [Internet]. 2017;8(44):76116–76128. Available from: http://www.oncotarget.com/fulltext/18814

46.

Murata T, Mekada E, Hoffman RM. Reconstitution of a metastatic-resistant tumor microenvironment with cancer-associated fibroblasts enables metastasis. Cell Cycle [Internet] 2017;16(6):533–535. Available from: https://doi.org/10.1080/15384101.2017.1281486

47.

Kashima H, Noma K, Ohara T, Kato T, Katsura Y, Komoto S, et al. Cancer-associated fibroblasts (CAFs) promote the lymph node metastasis of esophageal squamous cell carcinoma. Int J Cancer. 2018.

48.

Cohen N, Shani O, Raz Y, Sharon Y, Hoffman D, Abramovitz L, et al. Fibroblasts drive an immunosuppressive and growth-promoting microenvironment in breast cancer via secretion of Chitinase 3-like 1. Oncogene. 2017.

49.

Erez N, Glanz S, Raz Y, Avivi C, Barshack I. Cancer Associated Fibroblasts express pro-inflammatory factors in human breast and ovarian tumors. Biochem Biophys Res Commun. 2013.

50.

Balachander GM, Talukdar PM, Debnath M, Rangarajan A, Chatterjee K. Inflammatory Role of Cancer-Associated Fibroblasts in Invasive Breast Tumors Revealed Using a Fibrous Polymer Scaffold. ACS Appl Mater Interfaces. 2018;

51.

Lim H, Moon A. Inflammatory fibroblasts in cancer. Arch Pharm Res. 2016.

52.

Attieh Y, Clark AG, Grass C, Richon S, Pocard M, Mariani P, et al. Cancer-associated fibroblasts lead tumor invasion through integrin-beta3-dependent fibronectin assembly. J Cell Biol. 2017;216(11):1–12.

53.

McCarthy JB, El-Ashry D, Turley EA. Hyaluronan, Cancer-associated fibroblasts and the tumor microenvironment in malignant progression. Front Cell Dev Biol [Internet] 2018;6(May):1–13. Available from: https://doi.org/10.3389/fcell.2018.00048/full

54.

Zanconato F, Cordenonsi M, Piccolo S. YAP/TAZ at the Roots of Cancer. Cancer Cell. 2016.

55.

Calvo F, Ege N, Grande-Garcia A, Hooper S, Jenkins RP, Chaudhry SI, et al. Mechanotransduction and YAP-dependent matrix remodelling is required for the generation and maintenance of cancer-associated fibroblasts. Nat Cell Biol. 2013.

56.

Cadamuro M, Nardo G, Indraccolo S, Dall’Olmo L, Sambado L, Moserle L, et al. Platelet-derived growth factor-D and Rho GTPases regulate recruitment of cancer-associated fibroblasts in cholangiocarcinoma. Hepatology. 2013.

57.

Ge J, Burnier L, Adamopoulou M, Kwa MQ, Schaks M, Rottner K, et al. RhoA, Rac1, and Cdc42 differentially regulate SMA and collagen i expression in mesenchymal stem cells. J Biol Chem. 2018.

58.

Drifka CR, Loeffler AG, Mathewson K, Keikhosravi A, Eickhoff JC, Liu Y, et al. Highly aligned stromal collagen is a negative prognostic factor following pancreatic ductal adenocarcinoma resection. Oncotarget [Internet]. 2016;7(46). Available from: https://www.ncbi.nlm.nih.gov/pubmed/27776346

59.

Shiga K, Hara M, Nagasaki T, Sato T, Takahashi H, Takeyama H. Cancer-associated fibroblasts: their characteristics and their roles in tumor growth. Cancers (Basel) 2015;7(4):2443–2458.

60.

Heldin CH, Rubin K, Pietras K, Östman A. High interstitial fluid pressure - an obstacle in cancer therapy. Nat Rev Cancer. 2004;4(10):806–13.PubMed

61.

Fang M, Yuan J, Peng C, Li Y. Collagen as a double-edged sword in tumor progression. Tumor Biol. 2014;35(4):2871–82.

62.

Rhim AD, Oberstein PE, Thomas DH, Mirek ET, Palermo CF, Sastra SA, et al. Stromal elements act to restrain, rather than support, pancreatic ductal adenocarcinoma. Cancer Cell. 2014;25(6):735–47.PubMedPubMedCentral

63.

Özdemir BC, Pentcheva-Hoang T, Carstens JL, Zheng X, Wu CC, Simpson TR, et al. Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival. Cancer Cell. 2014;25(6):719–34.PubMedPubMedCentral

64.

Froeling FEM, Kocher HM. Homeostatic restoration of desmoplastic stroma rather than its ablation slows pancreatic cancer progression. Gastroenterology. 2015 Apr;148(4):849–50.PubMed

65.

Lo A, Wang L-CS, Scholler J, Monslow J, Avery D, Newick K, et al. Tumor-promoting Desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res. 2018;75(14):2800–10.

66.

Surowiak P, Murawa D, Materna V, Maciejczyk A, Pudelko M, Ciesla S, et al. Occurence of stromal myofibroblasts in the invasive ductal breast cancer tissue is an unfavourable prognostic factor. Anticancer Res. 2007;27(4 C):2917–24.PubMed

67.

Marsh D, Suchak K, Moutasim KA, Vallath S, Hopper C, Jerjes W, et al. Stromal features are predictive of disease mortality in oral cancer patients. J Pathol. 2011;223(4):470–81.PubMed

68.

Kellermann MG, Sobral LM, Silva SD da, Zecchin KG, Graner E, Lopes MA, et al. Myofibroblasts in the stroma of oral squamous cell carcinoma are associated with poor prognosis. Histopathology [Internet] 2007;51(6):849–853. Available from: https://doi.org/10.1111/j.1365-2559.2007.02873.x

69.

Tsujino T, Seshimo I, Yamamoto H, Chew YN, Ezumi K, Takemasa I, et al. Stromal myofibroblasts predict disease recurrence for colorectal cancer. Clin Cancer Res. 2007;13(7):2082–90.PubMed

70.

Saadi A, Shannon NB, Lao-Sirieix P, O’Donovan M, Walker E, Clemons NJ, et al. Stromal genes discriminate preinvasive from invasive disease, predict outcome, and highlight inflammatory pathways in digestive cancers. Proc Natl Acad Sci [Internet] 2010;107(5):2177–2182. Available from: https://doi.org/10.1073/pnas.0909797107

71.

Karsdal MA, Nielsen SH, Leeming DJ, Langholm LL, Nielsen MJ, Manon-Jensen T, et al. The good and the bad collagens of fibrosis – their role in signaling and organ function. Adv Drug Deliv Rev. 2017;121:43–56.PubMed

72.

Brisson BK, Mauldin EA, Lei W, Vogel LK, Power AM, Lo A, et al. Type III collagen directs stromal organization and limits metastasis in a murine model of breast cancer. Am J Pathol [Internet] 2015;185(5):1471–1486. Available from: https://doi.org/10.1016/j.ajpath.2015.01.029

73.

Chintala S, Sawaya R, Gokaslan Z, Rao J. The effect of type III collagen on migration and invasion of human. Cancer Lett. 1996;102:57–63.PubMed

74.

Hirai K, Shimada H, Ogawa T, Taji S. The spread of human lung cancer cells on collagens and its inhibition by type III collagen. Clin Exp Metastasis. 1991;9:517–27.PubMed

75.

Kanematsu A, Marui A, Yamamoto S, Ozeki M, Hirano Y, Yamamoto M, et al. Type I collagen can function as a reservoir of basic fibroblast growth factor. J Control Release. 2004;99(2):281–92.PubMed

76.

Zhao H, Han K-LL, Wang Z-YY, Chen Y, Li H-TT, Zeng J-LL, et al. Value of C-telopeptide-cross-linked type I collagen, osteocalcin, bone-specific alkaline phosphatase and procollagen type I N-terminal propeptide in the diagnosis and prognosis of bone metastasis in patients with malignant tumors. Med Sci Monit [internet]. 2011;17(11):CR626-CR633. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22037741.

77.

Cloos PAC, Fledelius C, Christgau S, Christiansen C, Engsig M. Delmas P, et al. Calcif Tissue Int: Investigation of bone disease using isomerized and racemized fragments of type I collagen; 2003.

78.

Hall CL, Dai J, van Golen KL, Keller ET, Long MW. Type I collagen receptor (alpha 2 beta 1) signaling promotes the growth of human prostate cancer cells within the bone. Cancer Res. 2006.

79.

Ferreira AR, Alho I, Shan N, Matias M, Faria M, Casimiro S, et al. N-Telopeptide of type I collagen Long-term dynamics in breast Cancer patients with bone metastases: clinical outcomes and influence of Extraskeletal metastases. Oncologist [Internet] 2016;21(12):1418–1426. Available from: https://doi.org/10.1634/theoncologist.2015-0527

80.

Zou X, Feng B, Dong T, Yan G, Tan B, Shen H, et al. Up-regulation of type I collagen during tumorigenesis of colorectal cancer revealed by quantitative proteomic analysis. J Proteomics [Internet]. 2013;94:473–485. Available from: https://doi.org/10.1016/j.jprot.2013.10.020

81.

Armstrong T, Packham G, Murphy LB, Bateman AC, Conti JA, Fine DR, et al. Type I collagen promotes the malignant phenotype of pancreatic ductal adenocarcinoma. ClinCancer Res [Internet] 2004;10(21):7427–7437. Available from: http://clincancerres.aacrjournals.org/cgi/content/abstract/10/21/7427

82.

Menke A, Philippi C, Vogelmann R, Seidel B, Lutz MP, Adler G, et al. Down-regulation of E-cadherin gene expression by collagen type I and type III in pancreatic Cancer cell lines 1. Biochemistry. 2001:3508–17.

83.

Cheng JC, Leung PCK. Type I collagen down-regulates E-cadherin expression by increasing PI3KCA in cancer cells. Cancer Lett. 2011.

84.

Gao H, Chakraborty G, Zhang Z, Akalay I, Gadiya M, Gao Y, et al. Multi-organ site metastatic reactivation mediated by non-canonical Discoidin domain receptor 1 signaling. Cell [Internet] 2016;166(1):47–62. Available from: https://doi.org/10.1016/j.cell.2016.06.009

85.

Barcus CE, O’Leary KA, Brockman JL, Rugowski DE, Liu Y, Garcia N, et al. Elevated collagen-I augments tumor progressive signals, intravasation and metastasis of prolactin-induced estrogen receptor alpha positive mammary tumor cells. Breast Cancer Res [Internet] 2017;19(1):1–13. Available from: https://doi.org/10.1186/s13058-017-0801-1

86.

Gelse K, Pöschl E, Aigner T. Collagens - structure, function, and biosynthesis. Adv Drug Deliv Rev. 2003.

87.

Key Statistics About Bone Cancer [Internet]. American Cancer Society. 2018. Available from: https://www.cancer.org/cancer/bone-cancer/about/key-statistics.html

88.

Hayashi S, Zhepeng W, Bryan J, Kobayashi C, Faccio R, Sandell L. The type II collagen N-propeptide, PIIBNP, inhibits cell survival and bone resorption of osteoclasts via integrin-mediated signaling. Bone. 2011;49(4):644–52.PubMedPubMedCentral

89.

Sipilä K, Haag S, Denessiouk K, Kap̈ylä J, Peters EC, Denesyuk A, et al. Citrullination of collagen II affects integrin-mediated cell adhesion in a receptor-specific manner. FASEB J. 2014;

90.

Wang Z, Bryan J, Franz C, Havlioglu N, Sandell LJ. Type IIB procollagen NH2-propeptide induces death of tumor cells via interaction with integrins αvβ3and αvβ5. J Biol Chem. 2010;285(27):20806–17.PubMedPubMedCentral

91.

Hilska M, Peltonen J, Gullichsen R, Paajanen H, Laato M. The Distribution of Collagen Types I , III , and IV in Normal and Malignant Colorectal Mucosa. 1998;

92.

Nurmenniemi S, Koivula M, Nyberg P, Tervahartiala T, Sorsa T. Type I and III collagen degradation products in serum predict patient survival in head and neck squamous cell carcinoma. Oral Oncol [Internet] 2012;48(2):136–140. Available from: https://doi.org/10.1016/j.oraloncology.2011.09.002

93.

Basso D, Belluco C, Mazza S, Greco E. Colorectal cancer metastatic phenotype stimulates production by fibroblasts of N-terminal peptide of type III collagen : clinical implications for prognosis. 2001;

94.

Jensen C, Madsen D, Hansen M, Schmidt H, Svane I, Karsdal M, et al. Altered type III collagen turnover measured in pre-treatment serum predicts outcome in metastatic melanoma patients treated with Ipilimumab. Eur J Cancer. 2018;92.

95.

Fichard A, Kleman JP, Ruggiero F. Another look at collagen V and XI molecules. Matrix Biology. 1995.

96.

Huang G, Ge G, Izzi V, Greenspan DS. α3 chains of type v collagen regulate breast tumour growth via glypican-1. Nat Commun [Internet] 2017;8:1–17. Available from: https://doi.org/10.1038/ncomms14351

97.

Cescon M, Gattazzo F, Chen P, Bonaldo P. Collagen VI at a glance. J Cell Sci [Internet] 2015;128(19):3525–3531. Available from: https://doi.org/10.1242/jcs.169748

98.

Chen P, Cescon M, Bonaldo P. Collagen VI in cancer and its biological mechanisms. Trends Mol Med [Internet] 2013;19(7):410–417. Available from: https://doi.org/10.1016/j.molmed.2013.04.001

99.

Park J, Scherer PE. Endotrophin – linking obesity with aggressive tumor growth. Oncotarget [Internet] 2012;33(12):1487–1488. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3681481/

100.

Schnoor M, Cullen P, Lorkowski J, Stolle K, Robenek H, Troyer D, et al. Production of type VI collagen by human macrophages: a new dimension in macrophage functional heterogeneity. J Immunol. 2008.

101.

Wright A, Li Y-H, Zhu C, Woodruff W, Coulter H. The differential effect of endothelial cell factors on in vitro motility of malignant and non-malignant cells. Ann Biomed Eng. 2008;36(6):958–69.PubMedPubMedCentral

102.

Han J. Daniel JC. Connect Tissue Res: Biosynthesis of type VI collagen by glioblastoma cells and possible function in cell invasion of three-dimensional matrices; 1995.

103.

Sherman-Baust CA, Weeraratna AT, Rangel LBA, Pizer ES, Cho KR, Schwartz DR, et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell. 2003;3(4):377–86.

104.

Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep. 2005.

105.

Park J, Morley TS, Scherer PE. Inhibition of endotrophin, a cleavage product of collagen VI, confers cisplatin sensitivity to tumours. EMBO Mol Med. 2013;5(6):935–48.PubMedPubMedCentral

106.

Iyengar P, Espina V, Williams TW, Lin Y, Berry D, Jelicks LA, et al. Adipocyte-derived collagen VI affects early mammary tumor progression in vivo, demonstrating a critical interaction in the tumor/stroma microenvironment. J Clin Invest. 2005;115(5):1163–76.PubMedPubMedCentral

107.

Sok JC, Lee JA, Dasari S, Joyce S, Contrucci SC, Egloff AM, et al. Collagen type XI α1 facilitates head and neck squamous cell cancer growth and invasion. Br J Cancer [Internet]. 2013;109(12):3049–56. Available from:. https://doi.org/10.1038/bjc.2013.624.

108.

Ellsworth RE, Seebach J, Field L a, Heckman C, Kane J, Hooke J a, et al. A gene expression signature that defines breast cancer metastases. Clin Exp Metastasis. 2009;

109.

Zhao Y, Zhou T, Li A, Yao H, He F, Wang L, et al. A potential role of collagens expression in distinguishing between premalignant and malignant lesions in stomach. Anat Rec. 2009.

110.

García-Pravia C, Galván JA, Gutiérrez-Corral N, Solar-García L, García-Pérez E, García-Ocaña M, et al. Overexpression of COL11A1 by Cancer-associated fibroblasts: clinical relevance of a stromal marker in pancreatic Cancer. PLoS One. 2013;8(10):1–13.

111.

Chong IW, Chang MY, Chang HC, Yu YP, Sheu CC, Tsai JR, et al. Great potential of a panel of multiple hMTH1, SPD, ITGA11 and COL11A1 markers for diagnosis of patients with non-small cell lung cancer. Oncol Rep. 2006.

112.

Fischer H. Colorectal carcinogenesis is associated with stromal expression of COL11A1 and COL5A2. Carcinogenesis. 2001.

113.

Vecchi M, Nuciforo P, Romagnoli S, Confalonieri S, Pellegrini C, Serio G, et al. Gene expression analysis of early and advanced gastric cancers. Oncogene. 2007.

114.

Badea L, Herlea V, Dima SO, Dumitrascu T, Popescu I. Combined gene expression analysis of whole-tissue and microdissected pancreatic ductal adenocarcinoma identifies genes specifically overexpressed in tumor epithelia. Hepatogastroenterology. 2008.

115.

Wu Y-H, Chang T-H, Huang Y-F, Huang H-D, Chou C-Y. COL11A1 promotes tumor progression and predicts poor clinical outcome in ovarian cancer. Oncogene. 2013.

116.

Kim H, Watkinson J, Varadan V, Anastassiou D. Multi-cancer computational analysis reveals invasion-associated variant of desmoplastic reaction involving INHBA, THBS2 and COL11A1. BMC Med Genet. 2010.

117.

Teng PN, Wang G, Hood BL, Conrads KA, Hamilton CA, Maxwell GL, et al. Identification of candidate circulating cisplatin-resistant biomarkers from epithelial ovarian carcinoma cell secretomes. Br J Cancer. 2014.

118.

Navab R, Strumpf D, Bandarchi B, Zhu C, Pintilie M, Rohan V. Prognostic gene-expression signature of carcinoma- associated fi broblasts in non-small cell lung cancer. Proc Natl Acad Sci U S A. 2011;108(april 26th):7160–5.

119.

Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, et al. A collagen-remodeling gene signature regulated by TGF-β signaling is associated with metastasis and poor survival in serous ovarian cancer. Clin Cancer Res. 2014.

120.

Ricard-Blum S, Ruggiero F. The collagen superfamily: from the extracellular matrix to the cell membrane. Pathol Biol. 2005;53(7):430–42.PubMed

121.

Koch M, Laub F, Zhou P, Hahn RA, Tanaka S, Burgeson RE, et al. Collagen XXIV , a Vertebrate Fibrillar Collagen with Structural Features of Invertebrate Collagens. J Biol Chem 2003;278(44):43236–44.

122.

Wang W, Olson D, Liang G, Franceschi RT, Li C, Wang B, et al. Collagen XXIV (Col24α1) promotes osteoblastic differentiation and mineralization.Pdf. Int J Biol Sci. 2012;8(10):1310–22.PubMedPubMedCentral

123.

Misawa K, Kabazawa T, Imai A, Endo S, Mochizuki D. Fukushima Hi, et al. Mol Clin Oncol: Prognostic value of type XXII and XXIV collagen mRNA expression in head and neck cancer patients; 2014.

124.

Pace JM, Corrado M, Missero C, Byers PH. Identification, characterization and expression analysis of a new fibrillar collagen gene, COL27A1. Matrix Biol. 2003.

125.

Plumb DA, Dhir V, Mironov A, Ferrara L, Poulsom R, Kadler KE, et al. Collagen XXVII is developmentally regulated and forms thin fibrillar structures distinct from those of classical vertebrate fibrillar collagens. J Biol Chem. 2007.

126.

Hjorten R, Hansen U, Underwood RA, Telfer HE, Fernandes RJ, Krakow D, et al. Type XXVII collagen at the transition of cartilage to bone during skeletogenesis. Bone. 2007.

127.

Ha SY, Yeo S-Y, Xuan Y, Kim S-H. The Prognostic Significance of Cancer-Associated Fibroblasts in Esophageal Squamous Cell Carcinoma. PLoS One [Internet]. 2014;9(6):e99955. Available from: https://doi.org/10.1371/journal.pone.0099955

128.

Paulsson J, Micke P. Prognostic relevance of cancer-associated fibroblasts in human cancer. Semin Cancer Biol [Internet]. 2014;25:61–68. Available from: https://doi.org/10.1016/j.semcancer.2014.02.006

129.

LeBleu VS, Kalluri R. A peek into cancer-associated fibroblasts: origins, functions and translational impact. Dis Model Mech [Internet]. 2018;11(4):dmm029447. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5963854/

130.

Arancio W, Belmonte B, Castiglia M, Napoli A Di. Liquid Biopsy in Cancer Patients 2017;41–49. Available from: https://doi.org/10.1007/978-3-319-55661-1

131.

Wang S, Willumsen N, Cecilie B, Karsdal M, Chondros D, Taverna D. Extracellular matrix (ECM) circulating peptide biomarkers as potential predictors of survival in patients (pts) with untreated metastatic pancreatic ductal adenocarcinoma (mPDA) receiving pegvorhyaluronidase alfa (PEGPH20), nab-paclitaxel (a), and gemcita. J Clin Oncol. 2018;36(15):–12030.

132.

Burchardt ER, Hein R, Bosserhoff AK. Laminin, hyaluronan, tenascin-C and type VI collagen levels in sera from patients with malignant melanoma. Clin Exp Dermatol. 2003.

133.

Kang CY, Wang J, Axell-House D, Soni P, Chu M-L, Chipitsyna G, et al. Clinical significance of serum COL6A3 in pancreatic ductal adenocarcinoma. J Gastrointest Surg. 2014.

134.

Bierie B, Moses HL. TGFβ the molecular Jekyll and Hyde.Pdf. Nat Rev Cancer. 2006;6.

135.

Borthwicka LA, Wynnb TA, Fishera AJ. Cytokine mediated tissue fibrosis. Biochim Biophys Acta. 2013;1832(7):1049–60.

136.

Mariathasan S, Turley S, Nickles D, Castiglioni A, Yuen K, Wang Y, et al. TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells. Nature. 2018;22(554):544–8.

Title: Collagens and Cancer associated fibroblasts in the reactive stroma and its relation to Cancer biology
Authors: Neel I. Nissen
Morten Karsdal
Nicholas Willumsen
Publication date: 01-12-2019
Publisher: BioMed Central
Keyword: Biomarkers
Published in: Journal of Experimental & Clinical Cancer Research / Issue 1/2019
Electronic ISSN: 1756-9966
DOI: https://doi.org/10.1186/s13046-019-1110-6

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

The LIM protein Ajuba/SP1 complex forms a feed forward loop to induce SP1 target genes and promote pancreatic cancer cell proliferation

E2A attenuates tumor-initiating capacity of colorectal cancer cells via the Wnt/beta-catenin pathway

Overexpression of RNF38 facilitates TGF-β signaling by Ubiquitinating and degrading AHNAK in hepatocellular carcinoma

Valproic acid exhibits anti-tumor activity selectively against EGFR/ErbB2/ErbB3-coexpressing pancreatic cancer via induction of ErbB family members-targeting microRNAs

ADAR1 promotes the epithelial-to-mesenchymal transition and stem-like cell phenotype of oral cancer by facilitating oncogenic microRNA maturation

Activation of dynamin-related protein 1 - dependent mitochondria fragmentation and suppression of osteosarcoma by cryptotanshinone

Keynote webinar | Spotlight on antibody–drug conjugates in cancer